Publications

1. Oral semaglutide (Rybelsus®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus

   The National Health Care Institute has completed its assessment whether oral semaglutide (Rybelsus®) is interchangeable with a ...

   Report | 29-05-2020

2. Specialist medicinal products assessment procedure

   Zorginstituut Nederland only assesses specialist medicinal products that pose a risk to the accessibility, affordability or ...

   Report | 11-05-2020

3. Pentosan polysulfate sodium (Elmiron®) for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions

   The National Health Care Institute has completed its assessment whether pentosan polysulfate sodium (Elmiron®) is interchangeable ...

   Report | 28-04-2020

4. 12 SQ-HDM SLIT (Itulazax®) for the treatment of allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group

   The National Health Care Institute has completed its assessment whether 12 SQ-HDM SLIT (Itulazax®) is interchangeable with a ...

   Report | 28-04-2020

5. Asfotase alfa (Strensiq ®) for the treatment of hypophosphatasia (HPP)

   The National Health Care Institute has completed its assessment whether asfotase alfa (Strensiq®) is interchangeable with a ...

   Report | 19-03-2020

6. Olaparib (Lynparza®) for the maintenance treatment of adult patients with carcinoma of the ovaries, tubes or peritoneum

   The National Health Care Institute has completed its assessment whether olaparib (Lynparza®) as a monotherapy for the maintenance ...

   Report | 19-03-2020

7. Trientine tetrahydrochloride (Cuprior®) the treatment of Wilson’s disease

   The National Health Care Institute has completed its assessment whether trientine tetrahydrochloride (Cuprior®) is ...

   Report | 19-03-2020

8. Hydroquinine (Inhibin®) for patients with nocturnal muscle cramps

   The National Health Care Institute has assessed whether hydroquinine (Inhibin®) should be included in the medication ...

   Report | 04-03-2020

9. Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations

   The National Health Care Institute has completed its assessment whether voretigene neparvovec (Luxturna®) for the treatment of ...

   Report | 17-02-2020

10. Emicizumab (Hemlibra®) for the prophylactic treatment of bleeding in patients with severe haemophilia A without inhibitors

    The National Health Care Institute has completed its assessment whether emicizumab (Hemlibra®) for the prophylactic treatment of ...

    Report | 17-02-2020